Live
FierceBiotechShionogi pays Apnimed $100M for joint venture to awaken sleep disorder dreamFierceBiotechOcugen eye disease gene therapy hits ph. 2 targets but underwhelms investorsEndpoints NewsOcugen heads to Phase 3 with gene therapy for geographic atrophyEndpoints NewsLessons from the last health tech revolutionEndpoints NewsFDA warns ImmunityBio over misleading podcast with Patrick Soon-ShiongThermo FisherThermo Fisher Scientific Completes Acquisition of Clario Holdings, Inc. - pharmiweb.comAgilentDirector Of Agilent Technologies Purchased $340K In Stock - BenzingaThermo FisherThermo Fisher Scientific (TMO) Completes Acquisition of Clario H - GuruFocusAgilentAgilent Technologies (A) to Acquire Biocare Medical for $950M - Insider MonkeyThermo FisherThermo Fisher Scientific (TMO) Partners With AIM ImmunoTech on Phase 3 Cancer Trial - Insider MonkeyEndpoints NewsKaryopharm’s mixed myelofibrosis data; Rezolute to seek FDA approval despite trial failureEndpoints NewsQ&A: Controversial embryo editing entrepreneur Cathy Tie on her new startup
Endpoints News Mar 24, 2026

Ocugen heads to Phase 3 with gene therapy for geographic atrophy

Ocugen heads to Phase 3 with gene therapy for geographic atrophy

Original
Body unavailable. Use the original source.

Directory

59 All